Cargando…
An Investigation on a Novel Anti-tumor Fusion Peptide of FSH(33-53)-IIKK
A novel fusion peptide FSH(33-53)-IIKK was designed and expected to combine the follicle stimulating hormone receptor (FSHR) targeting and tumor toxicity. In vitro and in vivo study showed the anti-tumor activity of FSH(33-53)-IIKK was enhanced compared to that of IIKK only. FSH(33-53)-IIKK could in...
Autores principales: | Yang, Runlin, Liu, Ping, Pan, Donghui, zhang, Pengjun, Bai, Zhicheng, Xu, Yuping, Wang, Lizhen, Yan, Junjie, Yan, Yongjun, Liu, Xingdang, Yang, Min |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910594/ https://www.ncbi.nlm.nih.gov/pubmed/27313792 http://dx.doi.org/10.7150/jca.14425 |
Ejemplares similares
-
PET Imaging of FSHR Expression in Tumors with (68)Ga-Labeled FSH1 Peptide
por: Pan, Donghui, et al.
Publicado: (2017) -
PET of HER2 Expression with a Novel (18)FAl Labeled Affibody
por: Xu, Yuping, et al.
Publicado: (2017) -
Targeting HER2-positive gastric cancer with a novel (18)F-labeled Z(HER2:342) probe
por: Pan, Yunyun, et al.
Publicado: (2019) -
Doxorubicin loaded ferritin nanoparticles for ferroptosis enhanced targeted killing of cancer cells
por: Yang, Runlin, et al.
Publicado: (2019) -
Synthesis of a novel (89)Zr-labeled HER2 affibody and its application study in tumor PET imaging
por: Xu, Yuping, et al.
Publicado: (2020)